5.1.1 Even as significant advances have been made in discrete technologies and process unit operations, considerable inefficiencies remain in the manufacture of recombinant biopharmaceuticals, resulting in suboptimal “time in plant” and facility throughput. Upstream and downstream processing capacities within and across facilities frequently fall into imbalance owing to the diversity of required custom processes, differences in productivity of cellular expression systems, and the nature of the product feed stream being delivered for purification. In addition, the frequent need to employ multi-vendor equipment across the process flow creates additional inefficiencies. In essence, these dynamics generate continual processing bottlenecks.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
5.2.1 As in many other aspects of biopharma discovery and development, digital technologies, most notably artificial intelligence (AI) and machine learning (ML), are playing a growing role in the discovery, design, and development of mAbs. Fully in silico mAb design leveraging AI and ML, to be truly effective, requires a deep understanding of the rules of mAb–antigen binding, the ability to combine different mAb design parameters in a modular fashion, and algorithms that enable unconstrained parameter-drivenmAb sequence synthesis. If done correctly, such antibody discovery tools can achieve fast, inexpensive, and on-demand generation of fit-for-purpose antibodies.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
5.3.1 The success of messenger RNA (mRNA) vaccines against COVID-19 has opened the door to many other potential mRNA-based vaccines and therapeutics. It has also drawn attention to the effectiveness of having the body produce the active drug or vaccine agent in vivo rather than via in vitro cell culture or bacterial/yeast fermentation. Researchers are consequently looking at ways to have healthy cells produce other drug substances, including antibodies.[28]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
5.4.1 Supporting all the above mentioned advances in bioprocessing technologies is the digital revolution. The biopharmaceutical manufacturing industry, supported by numerous specialist vendors, is now overcoming its initial reluctance to adopt electronic batch records (driven largely by validation and Title 21 Code of Federal Regulations [CFR] part 11 concerns). Continuing regulatory focus on data integrity during bioprocessing is accelerating the adoption of broad electronic documentation systems, laboratory information management systems (LIMS), and supply chain management and tracking.[98]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
5.5.1 One of the ongoing challenges in the biomanufacturing industry is a serious labor shortage. The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public–private partnership that was founded in 2017 to study, highlight, and address the challenges in the industry.[100] In 2022, NIIMBL published a study in which they surveyed manufacturers across the U.S. and found the talent shortage to be ubiquitous.[101] While the shortage is felt across all levels of biomanufacturing organizations, it is striking that only 42% of job postings for manufacturing associates require a bachelor’s degree.[101] Traditionally, firms across industries will pay relocation fees for high-level employees such as managers and above, but relocation support for entry-level employees without a college degree is rare. Companies are left, then, to recruit from local talent for entry-level manufacturing associates jobs while they simultaneously compete nationally (or even globally) for more educated talent.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
5.6.1 Related to the rise in high potency drugs are high concentration drugs, especially antibodies. High-concentration antibody products (HCAPs) represent a transformative development in the sterile biotherapeutics market. Defined in this discussion as injectable mAb therapies with concentrations above 100 mg/mL, HCAPs offer a unique combination of therapeutic efficacy and patient convenience. Unlike traditional IV therapies, which often require hospital visits or infusion centers, HCAPs enable subcutaneous (SC) self-administration, empowering patients with greater flexibility while significantly reducing healthcare costs. This patient-centric approach has made HCAPs a vital tool for managing chronic diseases, particularly those requiring long-term treatment.[113]
Development Challenges
5.6.2 Despite their advantages, the development of HCAPs is not without challenges. High protein concentrations introduce physical and chemical instabilities, such as viscosity, protein aggregation, and immunogenicity, which can compromise product efficacy and safety. Addressing these challenges requires robust formulation strategies, including the precise selection of excipients, optimization of stabilization techniques, and the application of advanced processing technologies. These measures ensure that HCAPs meet the rigorous quality and safety standards expected of sterile biotherapeutic products.
5.6.3 A systematic review of 46 FDA-approved HCAPs[114] highlights critical trends shaping their development and market adoption. Subcutaneous administration was found to be the predominant route, utilized by 34 products, reflecting the growing demand for patient-friendly, at-home treatments. Liquid formulations dominate the market, accounting for 41 of the 46 products, emphasizing a preference for ready-to-use solutions over lyophilized forms, which require additional preparation steps. Common formulation components include histidine as the leading buffer, sucrose as the primary tonicity agent, and polysorbate 80 as the most frequently used surfactant. Protein concentrations ranged from 100 to 200 mg/mL, with only a handful of products achieving the upper limit, highlighting ongoing innovation in balancing potency and stability.
Trends and Innovations
5.6.4 The evolution of HCAPs has been marked by significant innovations aimed at improving both delivery and patient outcomes. Ready-to-use liquid formulations have become the industry standard, driven by their convenience and ease of administration. Prefilled syringes, autoinjectors, and drug–device combination products are increasingly favored for their ability to simplify dosing and enhance patient adherence. Fixed-dose combination (FDC) therapies, such as REGEN-COV (Regeneron), have further streamlined treatment regimens by eliminating weight-based dose calculations, reducing potential errors. Moreover, technologies like ENHANZE (Halozyme) have expanded the scope of subcutaneous delivery, enabling larger dose volumes and offering a viable alternative to traditional IV administration.
5.6.5 HCAPs have been applied across a wide range of therapeutic areas, including immunology, oncology, neurology, infectious diseases, respiratory conditions, and cardiology. Immunology leads the field, with the majority of approved products targeting chronic autoimmune diseases such as rheumatoid arthritis and psoriasis. These therapies, designed for long-term management, benefit from the convenience of at-home administration, improving patient compliance and reducing healthcare system burdens. Additionally, HCAPs are making notable inroads in oncology and neurology, providing targeted treatments that address unmet medical needs.
5.6.6 The growing adoption of HCAPs highlights their pivotal role in the sterile biotherapeutics landscape. By addressing complex medical challenges with patient-centric solutions, HCAPs exemplify the convergence of innovation, convenience, and efficacy. As these products continue to evolve, they are poised to broaden their therapeutic reach and redefine treatment paradigms across multiple disease areas, solidifying their position as a cornerstone of modern biopharmaceutical development.
5.6.7 Prior to 2013, the majority (58%) of monoclonal antibody therapies approved by the FDA had concentrations between 0.1 mg/mL and 25 mg/mL. Since then, there has been a notable shift in this pattern. Among therapies approved between 2013 and 2024, 62% have concentrations above 25 mg/mL, with 34% in the medium range (25–100 mg/mL) and 28% in the high range (>100 mg/mL). This shift is further elucidated through year-by-year data since 2013 (Figure 24 and ), which show a sustained upward trend in the average concentration. Figure 23 also reflects this trend, demonstrating a clear skewing of the concentration distribution toward the higher end.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.